Speedel Receives Cost-Of-Goods Savings From Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
After dispute, Novartis will pay Speedel for savings in third-quarter production costs for Tekturna.
You may also be interested in...
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses Novartis’ hypertension treatment, Tekturna, which Speedel developed, as well as the benefits of other renin inhibitors in the Swiss biotech’s pipeline.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.